Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-THP-PSMA PET/CT in Prostate Cancer
NCT04158817Phase 1Completed
- Sponsor
- Shanghai General Hospital
- Start
- Nov 2019
- Primary completion
- Mar 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gallium-68 THP-PSMA in prostate cancer (PCa), sponsored by Shanghai General Hospital. Primary endpoints: Maximal Standard Uptake Value at 2 years, Measurement of Prostate-Specific Antigen at 2 years and 1 more. Started Nov 2019; status: completed.
02
Drugs
gallium-68 THP-PSMA
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04158817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04158817.